Abstract
Background: The rapid utilization of fibrinolytics following Q‐wave myocardial infarction has clearly modified the evolution of this disease. However, it is still not known whether the immediate inhibition of platelet aggregation (PA) during the coronary event improves outcomes.
Hypothesis: The present study was designed to test, in patients with known coronary artery disease (chronic stable angina), whether the particular kinetic pattern of lysine acetyl‐salicylate (LA) compared with aspirin may affect the time to onset of inhibition of platelet aggregation.
Methods: Ten patients suffering from chronic stable angina participated in this study to compare the efficacy and speed of the inhibition of PA with 320 mg of LA versus 320 mg of aspirin. All patients discontinued the use of aspirin and any other anti‐inflammatory agents for 15 days prior to the beginning of the study. They were randomly assigned to LA or aspirin. Blood specimens were obtained to measure the PA at admission, and 5,10,20,30, and 60 min after ingestion. Patients continued to take the assigned drug once a day for the following 4 days. On Day 5, a new blood sample was taken. After this, patients underwent a 15‐day wash‐out period, and then crossed over to the opposite drug. The samples were analyzed immediately using platelet‐rich plasma stimulated with adenosine diphosphate (ADP) 2 μmol/l, collagen 1 μg/ml, epinephrine 20 μmol/l, and sodium arachidonate acid 0.75 mm/l.
Results: The same level of PA inhibition after 30 and 60 min of aspirin administration can be obtained with LA 5 min following ingestion (sodium arachidonate acid: LA: 16.3 ± 25.9 vs. aspirin 57.6 ± 8.2; p = 0.00014; collagen: LA 18.9 ± 20.1 vs. aspirin 47.2 ± 10.5; p = 0.00092; ADP: LA 27.3 ± 18.4 vs. aspirin 39.7 ± 21.8, p = 0.18; epinephrine: LA 22.0 ± 9.9 vs. aspirin 55.4 ± 10.9, p = 0.00002.
Conclusions: Platelet aggregation inhibition immediately following LA may have significant clinical implications for the treatment of coronary syndromes.
Keywords: aspirin, lysine acetylsalicylate, angina, atherosclerosis, platelet inhibition, thrombosis
Full Text
The Full Text of this article is available as a PDF (403.8 KB).
References
- 1. Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico (GISSI) : Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet 1986; 1: 397–401 [PubMed] [Google Scholar]
- 2. Fibriolytic Therapy Trialists Collaborative Group : Indications for fibrinolytic therapy in suspected acute myocardial infarction: Collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1,000 patients. Lancet 1994; 343: 311–322 [PubMed] [Google Scholar]
- 3. The GUSTO Angiographic Investigators : The comparative effects of tissue plasminogen activator, streptokinase, or both on coronary artery patency, ventricular function and survival after acute myocardial infarction. N Engl J Med 1993; 329: 1615–1622 [DOI] [PubMed] [Google Scholar]
- 4. ISIS‐2 (Second International Study of Infarct Survival) Collaborative Group : Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction. Lancet 1988; ii: 349–360 [PubMed] [Google Scholar]
- 5. Faigel DJ, Jakulawski JA, Stampfer MJ, Vaillancourt R, Deykin D: Multiple doses of regular and enteric‐coated aspirin produce equivalent platelet inhibitory effects. Curr Ther Res 1986; 39: 519–527 [Google Scholar]
- 6. Jakulawski JA, Stampfer MJ, Vaillancourt R, Deykin D: Cumulative antiplatelet effect of low‐dose enteric‐coated aspirin. Br J Haematol 1985; 60: 635–642 [DOI] [PubMed] [Google Scholar]
- 7. Roussel B, Delobel J, Sangosse J, Dieval J, Claise JF, Liendard J: Effect de 2 doses d'acetylsalicylate de lysine sur l'agregation plaquettaire, la β‐thromboglobuline et le facteur plaquettaire 4 chez des sujets agés atherosclereux. Thérapie 1988; 43: 267–271 [PubMed] [Google Scholar]
- 8. Korttila K, Pentti OM, Auvien J: Comparison of IM lysine acetyl‐salicylate and oxycodone in the treatment of pain after operation. Br J Anaesth 1980; 52: 613–617 [DOI] [PubMed] [Google Scholar]
- 9. Aarons L, Hopkins K, Rowland M, Brossel S, Thiercelin JF: Route of administration and sex differences in the pharmacokinetics of aspirin, administered as its lysine salt. Pharm Res 1989; 6 (8): 660–666 [DOI] [PubMed] [Google Scholar]
- 10. Patrono C, Ciabattoni G, Pinca E: Low dose aspirin and inhibition of thromboxane B2 production in healthy subjects. Thromb Res 1980; 17: 317–327 [DOI] [PubMed] [Google Scholar]
- 11. Patrignani P, Flabozzi P, Patrono C: Selective cumulative inhibition of platelet thromboxane production by low‐dose aspirin in healthy subjects. J Clin Invest 1982; 69: 1366–1372 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12. De Caterina R, Giannessi D, Boem A: Equal antiplatelet effects of aspirin 50 or 324 mg/day in patients after acute myocardial infarction. Thromb Haemost 1985; 54: 528–532 [PubMed] [Google Scholar]
- 13. De Caterina R, Giannessi D, Bernini W: Low‐dose aspirin in patients recovering from myocardial infarction: Evidence for selective inhibition of thromboxane‐related platelet function. Eur Heart J 1985; 6: 409–417 [DOI] [PubMed] [Google Scholar]
- 14. Jimenez AH, Stubbs ME, Tofler GH, Winther K, Williams GH, Muller JE: Rapidity and duration of platelet suppression by enteric‐coated aspirin in healthy young men. Am J Cardiol 1992; 69: 258–262 [DOI] [PubMed] [Google Scholar]
- 15. Gatti G, Barzaghi N, Parrinello G, Vitiello B, Perucca E: Pharmacokinetics of salicylic acid following administration of aspirin tablets and three different forms of soluble aspirin in normal subjects. Int J Clin Pharm Res 1989; IX (6): 385–389 [PubMed] [Google Scholar]
- 16. Pedersen AK, FitzGerald GA: Dose‐related kinetics of aspirin. Presystemic acetylation of platelet cyclooxygenase. N Engl J Med 1984; 311: 1206–1211 [DOI] [PubMed] [Google Scholar]